Want to see ACRV full AI Analyst Report?
Top Page
Acrivon Therapeutics, Inc.
(NASDAQ:ACRV)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-27.18% Downside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by weak financial performance (no revenue, large losses, and persistent cash burn), partially mitigated by low leverage and positive equity. Technicals are supportive in the short term (price above key moving averages and positive MACD) but are tempered by overbought signals (high RSI/Stoch). Corporate actions add potential dilution risk via an expanded equity plan, while valuation metrics are constrained by negative earnings and no dividend data.
Positive Factors
Precision oncology platform
Acrivon’s proprietary proteomics-based AP3 platform provides a differentiated approach to precision oncology by linking drug response signatures with patient selection. If validated clinically, this capability could improve development efficiency and support more targeted therapies across the company’s pipeline.
Negative Factors
No product revenue
The absence of revenue means Acrivon currently lacks operating income from approved medicines and cannot demonstrate commercial demand or operating leverage. Progress therefore depends heavily on clinical execution and future financing or partnership proceeds until a candidate reaches potential commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Precision oncology platform
Acrivon’s proprietary proteomics-based AP3 platform provides a differentiated approach to precision oncology by linking drug response signatures with patient selection. If validated clinically, this capability could improve development efficiency and support more targeted therapies across the company’s pipeline.
Read all positive factors
Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.56M
Dividend YieldN/A
Average Volume (3M)281.83K
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue GrowthN/A
EPS Growth16.04%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.88
Shares Outstanding42,853,363
10 Day Avg. Volume187,528
30 Day Avg. Volume281,835
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.31
Enterprise Value/Ebitda0.17
Forecast
1Y Price Target
$10.50Price Target Upside409.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.85
Revenue Forecast (FY)N/A
Acrivon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific med...
How the Company Makes Money
Acrivon Therapeutics does not have publicly confirmed recurring product revenue because it is a clinical-stage drug developer and its pipeline consists of investigational candidates that are not approved for commercial sale. As a result, the compa...
Acrivon Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 528.00K | -1.36M | -1.01M | -536.00K | 0.00 | 0.00 |
| EBITDA | -78.94M | -76.55M | -79.55M | -59.85M | -30.80M | -16.21M |
| Net Income | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
Balance Sheet | ||||||
| Total Assets | 99.09M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Cash, Cash Equivalents and Short-Term Investments | 89.96M | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Total Debt | 2.12M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Total Liabilities | 12.43M | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Stockholders Equity | 86.67M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
Cash Flow | ||||||
| Free Cash Flow | -64.14M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Operating Cash Flow | -62.92M | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Investing Cash Flow | 55.51M | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Financing Cash Flow | 6.93M | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
Acrivon Therapeutics, Inc. Technical Analysis
Negative
2.06
Price Trends
1.97
Negative
1.83
Negative
1.77
Negative
Market Momentum
-0.06
Positive
42.68
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Negative. The current price of 2.06 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.97, and above the 200-day MA of 1.77, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.68 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRV.
Acrivon Therapeutics, Inc. Risk Analysis
Acrivon Therapeutics, Inc. disclosed 82 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acrivon Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
ACRV
Acrivon Therapeutics, Inc.
1.74
-0.24
-12.12%
MNOV
Medicinova
1.41
0.20
16.53%
ALGS
Aligos Therapeutics
4.74
-4.58
-49.14%
GNTA
Genenta Science SpA Sponsored ADR
0.62
-1.78
-74.25%
IMMX
Immix Biopharma
8.05
4.15
106.41%
CAMP
CAMP4 Therapeutics Corporation
3.65
-0.26
-6.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.